Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and IO102/IO103 Vaccine in Metastatic Melanoma
NCT03047928Phase 2Completed
- Start
- Feb 2018
- Primary completion
- Dec 2022
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PD-L1/IDO peptide vaccine in melanoma. Started Feb 2018; status: completed.
02
Drugs
PD-L1/IDO peptide vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03047928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03047928.